Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-IMH
NCT05986968Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of ticagrelor in ST elevation myocardial infarction (STEMI) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Composite of major adverse cardiac and cerebral events at 13 months and Intramyocardial haemorrhage. Started Jul 2023; status: active, not recruiting.
02
Drugs
ticagrelor
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05986968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05986968.